Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences
November 07 2017 - 7:30AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) a clinical-stage
specialty pharmaceutical company dedicated to developing and
commercializing innovative pharmaceutically-produced transdermal
cannabinoid treatments, today announced that Armando Anido,
Chairman and Chief Executive Officer, will provide a company
overview at two investor conferences in November:
- Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017
at 5:00 p.m. ET at the Lotte New York Palace in New York, NY
- 29th Annual Piper Jaffray Healthcare Conference on Tuesday,
November 28, 2017 at 10:30 a.m. at the Lotte New York Palace in New
York, NY
To listen to a webcast of either presentation live, please visit
the Investor Relations page of www.zynerba.com. A replay of the
webcast will be available for 90 days following the conclusion of
the event.
About Zynerba Pharmaceuticals, Inc. Zynerba
Pharmaceuticals (NASDAQ:ZYNE) is dedicated to improving the lives
of people with severe health conditions where there is a high unmet
medical need by developing and commercializing
pharmaceutically-produced transdermal cannabinoid medicines
designed to meet the rigorous efficacy and safety standards
established by global regulatory agencies. Through the discovery
and development of these life-changing medicines, Zynerba seeks to
improve the lives of patients battling severe, chronic health
conditions including epilepsy, Fragile X syndrome, osteoarthritis,
fibromyalgia and peripheral neuropathic pain. Learn more at
www.zynerba.com and follow the Company on Twitter at
@ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. For example, there can be no guarantee that the
Company will obtain approval for ZYN002 or ZYN001 from the U.S.
Food and Drug Administration (FDA) or foreign regulatory
authorities; even if ZYN002 or ZYN001 are approved, the Company may
not be able to obtain the label claims that it is seeking from the
FDA. In addition, the Company’s cash and cash equivalents may not
be sufficient to support its operating plan for as long as
anticipated. Management’s expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
factors, including the following: the success, cost and timing of
the Company’s product development activities, studies and clinical
trials; the success of competing products that are or become
available; the Company’s ability to commercialize its product
candidates; the size and growth potential of the markets for the
Company’s product candidates, and the Company’s ability to service
those markets; the Company’s ability to develop sales and marketing
capabilities, whether alone or with potential future collaborators;
the rate and degree of market acceptance of the Company’s product
candidates; and the Company’s expectations regarding its ability to
obtain and adequately maintain sufficient intellectual property
protection for its product candidates. This list is not exhaustive
and these and other risks are described in the Company’s periodic
reports, including the annual report on Form 10-K, quarterly
reports on Form 10-Q and current reports on Form 8-K, filed with or
furnished to the Securities and Exchange Commission and available
at www.sec.gov. Any forward-looking statements that the
Company makes in this press release speak only as of the date of
this press release. The Company assumes no obligation to update
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Investor Contact
Will Roberts, VP Investor Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024